Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
10.5 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
21 mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
31mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
42mg budesonide effervescent tablet for orodispersible use1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
55 mg Montelukast1件: Montelukast1件: Montelukast 💬1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98 💬
6AK002----1件: 98 💬
7Allergy immunotherapy (allergy shots)----1件: 98 💬
8Alpha-proteinase inhibitor----1件: 98 💬
9AMG 1571件: Tezepelumab1件: Tezepelumab 💬1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
10AMG157----1件: 98 💬
11APD334----5件: 93, 96, 97, 98, 269 💬
12APT-1011----1件: 98 💬
13APT-1011 - 3 mg----1件: 98 💬
14APT-1011 3 mg HS----1件: 98 💬
15AQ280----1件: 98 💬
16AR401959 L-arginine2件: Arginine,
L-arginine		1件: Arginine 💬--3件: 96, 97, 98 💬
17Arginine1件: Arginine1件: Arginine 💬--11件: 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299 💬
18Baked Milk1件: Cow milk---1件: 98 💬
19Barzolvolimab----1件: 98 💬
20Beclomethasone dipropionate1件: Beclomethasone dipropionate1件: Beclomethasone dipropionate 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 97, 98 💬
21Benralizumab1件: Benralizumab1件: Benralizumab 💬1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
22Bethanechol1件: Bethanechol---1件: 98 💬
23BT----3件: 96, 97, 98 💬
24BT-11 1000mg----3件: 96, 97, 98 💬
25BT-11 500mg----1件: 98 💬
26BUDESONIDE1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
27Budesonide 0.5 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
28Budesonide 0.5 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
29Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
30Budesonide 1 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
31Budesonide 1 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
32Budesonide 1 mg orodispersible tablets (BUL 1 mg)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
33Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
34Budesonide 2 mg orodispersible tablets (BUL 2 mg)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
35Budesonide [0.4mg/ml] viscous suspension1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
36Budesonide Gel1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
37Budesonide oral suspension1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
38Budesonide oral suspension [0.2 mg/ml]1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
39Budesonide Orodispersible Tablets (Jorveza)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
40Budesonide plus Prevacid1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
41BUET 0.5 mg----1件: 98 💬
42BUET 1 mg----1件: 98 💬
43BUET 1mg----1件: 98 💬
44BUET 2mg----1件: 98 💬
45BUL 0.5 mg----1件: 98 💬
46BUL 1 mg----1件: 98 💬
47BUU 0.4mg/ml----1件: 98 💬
48CALY-002----1件: 98 💬
49CC----13件: 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 💬
50CC-93538----1件: 98 💬
51Cendakimab----1件: 98 💬
52Citalopram1件: Citalopram1件: Citalopram 💬1件: SLC6A4 💬2件: Serotonergic synapse, Synaptic vesicle cycle 💬7件: 6, 8, 13, 18, 46, 98, 127 💬
53Compressa effervescente 0,5 mg di budesonide per uso orodispersibile1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
54Compressa effervescente 1 mg di budesonide per uso orodispersibile1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
55Cromolyn1件: Cromoglicic acid1件: Cromoglicic acid 💬--3件: 2, 85, 98 💬
56CYP substrates----1件: 98 💬
57Dexlansoprazole1件: Dexlansoprazole1件: Dexlansoprazole 💬2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98 💬
58Dupilumab1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬5件: 51, 97, 98, 160, 162 💬
59Dupilumab (blinded)1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98 💬
60Dupilumab (open-label)1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98 💬
61Dupixent1件: Dupilumab1件: Dupilumab 💬1件: IL4R 💬8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬3件: 98, 160, 162 💬
62Else nutrition formula----1件: 98 💬
63Eosinophilic Esophagitis (E0E) food introduction-2nd----1件: 98 💬
64Eosinophilic Esophagitis (EoE) food introduction-1st----1件: 98 💬
65Eosinophilic Esophagitis (EoE) Food introduction-3rd dose----1件: 98 💬
66EP-104IAR----1件: 98 💬
67ESO-101----1件: 98 💬
68Esomeprazole1件: Esomeprazole1件: Esomeprazole 💬2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬8件: 13, 46, 86, 98, 107, 113, 298, 299 💬
69Etrasimod1件: Etrasimod1件: Etrasimod 💬5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98 💬
70Etrasimod L-arginine3件: Arginine,
Etrasimod,
L-arginine		2件: Arginine ,
Etrasimod 💬		5件: S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 96, 97, 98 💬
71EUR-1100----1件: 98 💬
72Famotidine1件: Famotidine1件: Famotidine 💬1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬5件: 6, 46, 86, 98, 107 💬
73Fasenra1件: Benralizumab1件: Benralizumab 💬1件: IL5RA 💬4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬5件: 44, 45, 98, 162, 299 💬
74Florence 30 µg/mL----1件: 98 💬
75Florence 60 µg/mL----1件: 98 💬
76Florence 90 µg/mL----1件: 98 💬
77Flovent----1件: 98 💬
78Fluticasone2件: Fluticasone,
Fluticasone propionate		2件: Fluticasone propionate ,
Fluticasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 98, 228, 299 💬
79Fluticasone MDI1件: Fluticasone1件: Fluticasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
80FLUTICASONE PROPIONATE2件: Fluticasone,
Fluticasone propionate		2件: Fluticasone propionate ,
Fluticasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 228 💬
81Fluticasone Propionate, USP2件: Fluticasone,
Fluticasone propionate		2件: Fluticasone propionate ,
Fluticasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
82Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 💬
83High dose budesonide suspension1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
84High dose budesonide tablet1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
85Infliximab1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
86Inhaled/swallowed budesonide1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
87Intubated with Propofol (IP)1件: Propofol1件: Propofol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬1件: 98 💬
88Intubated with Sevoflurane (IS)1件: Sevoflurane1件: Sevoflurane 💬--1件: 98 💬
89IRL201104----1件: 98 💬
90Jorveza1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
91Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
92Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
93Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
94Jorveza 1 mg orodispersible tablets1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
95L-arginine2件: Arginine,
L-arginine		1件: Arginine 💬--8件: 46, 67, 78, 96, 97, 98, 113, 299 💬
96Lansoprazole1件: Lansoprazole1件: Lansoprazole 💬2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬7件: 63, 71, 85, 98, 166, 222, 299 💬
97Lirentelimab1件: Lirentelimab1件: Lirentelimab 💬1件: SIGLEC8 💬-1件: 98 💬
98Lirentelimab (AK002)1件: Lirentelimab1件: Lirentelimab 💬1件: SIGLEC8 💬-1件: 98 💬
99Loratadine1件: Loratadine1件: Loratadine 💬1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬4件: 13, 46, 89, 98 💬
100Losartan1件: Losartan1件: Losartan 💬1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
101LOSARTAN POTASSIUM2件: Losartan,
Potassium		2件: Losartan ,
Potassium 💬		1件: AGTR1 💬16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬5件: 36, 98, 167, 179, 215 💬
102Low dose budesonide tablet1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
103MEDI-563----5件: 44, 45, 98, 162, 299 💬
104MEDI99291件: Tezepelumab1件: Tezepelumab 💬1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
105MEDI9929 anti-TSLP mAb (AMG157)1件: Tezepelumab1件: Tezepelumab 💬1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
106MEPOLIZUMAB1件: Mepolizumab1件: Mepolizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬4件: 44, 45, 98, 162 💬
107Mepolizumab 100 mg1件: Mepolizumab1件: Mepolizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98 💬
108Mepolizumab 300 mg1件: Mepolizumab1件: Mepolizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬1件: 98 💬
109Mesalamine1件: Mesalazine1件: Mesalamine 💬--4件: 96, 97, 98, 164 💬
110Mesalamine Oral Product1件: Mesalazine1件: Mesalamine 💬--1件: 98 💬
111Milk1件: Cow milk---1件: 98 💬
112Mometasone2件: Mometasone,
Mometasone furoate		2件: Mometasone furoate ,
Mometasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162 💬
113MOMETASONE FUROATE2件: Mometasone,
Mometasone furoate		2件: Mometasone furoate ,
Mometasone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬2件: 98, 162 💬
114Montelukast1件: Montelukast1件: Montelukast 💬1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬8件: 6, 13, 46, 61, 63, 85, 98, 228 💬
115Montelukast/ Singulair1件: Montelukast1件: Montelukast 💬1件: CYSLTR1 💬2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬1件: 98 💬
116Nasonex----1件: 98 💬
117OC000459----1件: 98 💬
118OMALIZUMAB1件: Omalizumab1件: Omalizumab 💬1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299 💬
119Oral Budesonide1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
120Oral Budesonide Suspension (MB-9)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
121Oral Budesonide Suspension (OBS)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
122Oral cromolyn sodium1件: Cromoglicic acid1件: Cromoglicic acid 💬--1件: 98 💬
123Oral Viscous Budesonide1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
124Oral Viscous Budesonide (OVB)1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
125Picoprep----1件: 98 💬
126Potassium1件: Potassium1件: Potassium 💬--13件: 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235 💬
127PROPOFOL1件: Propofol1件: Propofol 💬16件: GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬8件: 6, 21, 22, 34, 46, 70, 98, 296 💬
128QAX576----4件: 51, 85, 96, 98 💬
129Reslizumab1件: Reslizumab1件: Reslizumab 💬1件: IL5 💬13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬2件: 44, 98 💬
130RPC4046----1件: 98 💬
131SB-240563----3件: 44, 45, 98 💬
132SCH55700----1件: 98 💬
133Sevoflurane1件: Sevoflurane1件: Sevoflurane 💬--7件: 6, 21, 22, 34, 98, 225, 296 💬
134Sirolimus1件: Sirolimus1件: Sirolimus 💬1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬35件: 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331 💬
135Steroid and Proton Pump Inhibitor Therapy----1件: 98 💬
136Sucralfate1件: Sucralfate1件: Sucralfate 💬--1件: 98 💬
137Swallowed fluticasone1件: Fluticasone1件: Fluticasone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
138Tezepelumab1件: Tezepelumab1件: Tezepelumab 💬1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
139Tezepelumab via APFS1件: Tezepelumab1件: Tezepelumab 💬1件: TSLP 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬1件: 98 💬
140Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms1件: Lansoprazole1件: Lansoprazole 💬2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬1件: 98 💬
141Viaskin Milk 500 mcg1件: Cow milk---1件: 98 💬
142Viscous/swallowed budesonide1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
143Vonoprazan1件: Vonoprazan1件: Vonoprazan 💬2件: ATP4A,
ATP4B 💬		4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 63, 98 💬
144Zofran - no intubation----1件: 98 💬